February

05
2015

9:00 am EST - 3:00 pm EST

Past Event

Sentinel Initiative Public Workshop

  • Thursday, February 5, 2015

    9:00 am - 3:00 pm EST

Washington Plaza Hotel

10 Thomas Circle, NW
Washington, DC
20005

The Food and Drug Administration Amendments Act of 2007 mandated that the U.S. Food and Drug Administration (FDA) develop a national electronic system to track the safety of regulated medical products. In response, FDA launched the Sentinel Initiative in 2008. Mini-Sentinel, a pilot project of the Sentinel Initiative, uses electronic health care data for postmarket risk identification and analysis of medical product safety.

On February 5, the Engelberg Center for Health Care Reform at Brookings hosted the seventh annual Sentinel Initiative Public Workshop at the Washington Plaza Hotel in Washington, DC. This event served as a forum for leading experts and stakeholders to discuss the current state of the Mini-Sentinel activities; explore stakeholder perspectives on the future of Sentinel; and identify opportunities to expand its use. Dr. Janet Woodcock, the Director of the Center for Drug Evaluation and Research at FDA, provided the morning keynote address.

twitter logo Join the conversation at @BrookingsMed or #Sentinel

Stakeholder Perspectives on the Future of the Sentinel System

Agenda

  • February 5
    • Strengthening Support for Sentinel's Infrastructure through New Uses

      1:45 pm - 3:00 pm

      MDW
      Marcus D. Wilson President - HealthCore
      RLF
      Rachael L. Fleurence Program Director, Comparative Effectiveness Research Methods & Infrastructure - Patient-Centered Outcomes Research Institute
      DW
      David Wheadon Senior Vice President and Head of Global Regulatory Affairs, Patient Safety and Quality Assurance - AstraZeneca Pharmaceuticals
      CV
      Claudia Vellozzi Chief, Prevention Branch - Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention
      CKC
      Christine K. Cassel President and CEO - National Quality Forum
    • Keynote Address

      9:15 am - 9:30 am

      JW
      Janet Woodcock Director, Center for Drug Evaluation and Research - US Food and Drug Administration
    • State of Mini-Sentinel Activities

      9:30 am - 11:00 am

      RP
      Richard Platt Professor and Chair, Department of Population Medicine - Harvard Pilgrim Health Care Institute
      MER
      Marsha E. Reichman Senior Advisor and Scientific Lead for Surveillance Programs - Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administraion
      MDN
      Michael D. Nguyen Deputy Director, Division of Epidemiology, Office of Biostatistics and Epidemiology - Center for Biologics Evaluation and Research, US Food and Drug Administration
    • Break

      11:00 am - 11:15 am

      RP
      Richard Platt Professor and Chair, Department of Population Medicine - Harvard Pilgrim Health Care Institute
      MER
      Marsha E. Reichman Senior Advisor and Scientific Lead for Surveillance Programs - Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administraion
      MDN
      Michael D. Nguyen Deputy Director, Division of Epidemiology, Office of Biostatistics and Epidemiology - Center for Biologics Evaluation and Research, US Food and Drug Administration
    • Stakeholder Perspectives on the Future of the Sentinel System

      11:15 am - 12:45 pm

      KMM
      Karla M. Miller Assistant VP, Pharmacy Services and Clinical Therapeutics - Hospital Corporation of America, Clinical Services Group
      JPD
      Joseph P. Drozda Director of Outcomes Research - Mercy Health
      MW
      Myrl Weinberg Chief Executive Officer - National Health Council
      SFT
      Sharon F. Terry President and Chief Executive Officer - Genetic Alliance
      RFR
      Robert F. Reynolds Vice President and Global Head, Epidemiology in Worldwide Safety - Pfizer, Inc.
      TM
      Troy McCall Chief Implementation Officer, Innovation in Medical Evidence Development and Surveillance - Reagan-Udall Foundation for the FDA
    • Lunch

      12:45 pm - 1:45 pm

      KMM
      Karla M. Miller Assistant VP, Pharmacy Services and Clinical Therapeutics - Hospital Corporation of America, Clinical Services Group
      JPD
      Joseph P. Drozda Director of Outcomes Research - Mercy Health
      MW
      Myrl Weinberg Chief Executive Officer - National Health Council
      SFT
      Sharon F. Terry President and Chief Executive Officer - Genetic Alliance
      RFR
      Robert F. Reynolds Vice President and Global Head, Epidemiology in Worldwide Safety - Pfizer, Inc.
      TM
      Troy McCall Chief Implementation Officer, Innovation in Medical Evidence Development and Surveillance - Reagan-Udall Foundation for the FDA